Clinical trials: Cystic Fibrosis (CF)
Cystic Fibrosis, Digestive System Disease
A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF
Development of a new patient reported outcome measure (PROM) that will measure the daily burden of gastrointestinal symptoms over the previous 24 hour period for people with cystic fibrosis.
- Conditions
- Cystic Fibrosis, Digestive System Disease, Genetic Disease, Respiratory Tract Diseases
- Trial name
- CARDS-CF (NCT05251467)
- Testing
- Focus group, Patient interview (n = approximately 10), Questionnaire (n = 180)
- Where
- United Kingdom
- Volunteers
- 350 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Cystic Fibrosis (CF)
Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis
The goal of this clinical trial is to support the development of personalized therapy tailored to each patient's individual characteristics.
- Trial name
- NCT07809867
- Testing
- Elexacaftor, Tezacaftor, Ivacaftor, Ivacaftor (VX-770)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Istituto Giannina Gaslini
Cystic Fibrosis (CF)
MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure .
This study is being done to determine whether MRI can produce high quality lung and airway images in healthy and CF patients and if MRI can be used to evaluate size and shape of the airways with computer assistance.
- Trial name
- UTE Airway MR (NCT07454681)
- Testing
- Advanced ultrashort echo time (UTE) MRI - Ultrashort echo time (UTE) imaging is a technique that can quickly capture the fast-decaying 1H lung signal., Multiple Breath Wash out (MBW)
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Cystic Fibrosis
Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function
Malnutrition is a significant problem in children and adults with Cystic fibrosis (CF). An impaired intestinal digestion and absorption capacity is one of the main factors responsible for the malnutrition in CF.
- Trial name
- NCT01494909
- Testing
- Ensure plus
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age
A study to determine the safety, effectiveness, and acceptability of 2 methods of administration of EUR-1008 (APT-1008) (Zenpep® [pancrelipase] delayed release capsule) 3,000 lipase units capsule, a pancreatic enzyme product…
- Trial name
- NCT01100606
- Testing
- EUR-1008 (APT-1008)
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Forest Laboratories
Hearing Loss, Sensorineural, Cystic Fibrosis
A Study of Web and Tablet-based Interactive Audiometry in Adults With CF
Adults with CF regularly receive anti-infective therapy that can result in impaired hearing. Recent studies have identified that up to 50% of adults with CF have hearing loss with resulting significant impact on quality of life.
- Trial name
- NCT04400955
- Testing
- Audiometry tablet diagnostic tool and web-based test
- Where
- United Kingdom
- Volunteers
- 156 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cystic Fibrosis (CF), Pregnancy
A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring
In this study, investigators aim to study in detail the physical (including nutritional and pulmonary) and mental health of females with cystic fibrosis (CF) planning a pregnancy, during pregnancy, and in the early parenthood…
- Conditions
- Cystic Fibrosis (CF), Pregnancy, Infant, Newborn, Exposure During Pregnancy
- Trial name
- MATRIARCH_CF (NCT06797206)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cystic Fibrosis
Effects of AD on VI in Patients With CF
This study will investigate the effects of a chest physiotherapy manual technique (autogenic drainage) on ventilation inhomogeneity in patients with cystic fibrosis. Lung clearance index (LCI) is the primary outcome
- Trial name
- NCT03655249
- Testing
- Autogenic drainage, Aerosoltherapy
- Where
- Belgium
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cystic Fibrosis, Hypoestrogenism
Estrogen Supplementation and Bone Health in Women With CF
The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF).
- Trial name
- STURDY (NCT05704036)
- Testing
- Transdermal estrogen, Progesterone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University
Cystic Fibrosis
Investigation of Relationship Between Vascular Functions, Exercise Capacity, and Respiratory Functions in CF
In the literature, there is no study that evaluates the endothelial function and arterial stiffness together and investigates its relationship with exercise capacity and respiratory functions in children with CF of different…
- Trial name
- NCT04259983
- Testing
- Maximal exercise test, Endothelial dysfunction assessment, Arterial stiffness assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Hacettepe University
Cystic Fibrosis
Orkambi Treatment in 2 to 5 Year Old Children With CF
The purpose of this observational research study is to determine the effects of clinically prescribed Orkambi treatment on 2 to 5 year old children homozygous for the F508del Mutations in the Cystic fibrosis transmembrane…
- Trial name
- NCT03795363
- Testing
- Orkambi
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Hospital of Philadelphia
Cystic Fibrosis Related Diabetes
Genetic Modifiers of Cystic Fibrosis Related Diabetes
This research is being done to find the genes and other factors that are responsible for differences among persons with cystic fibrosis.
- Trial name
- NCT01113216
- Where
- 3 sites in United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Cystic Fibrosis
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation
The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following…
- Trial name
- KONNECTION (NCT01614470)
- Testing
- Ivacaftor
- Where
- 12 sites in United States, Belgium and 1 more
- Volunteers
- 39 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pulmonary Infections, Pseudomonas Aeruginosa
Second Open Label Extension to Bridging Study CTBM100C2303
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 and extension study one CTBM100C2303E1 (all visits), who were…
- Trial name
- NCT01069705
- Testing
- Tobramycin inhalation powder
- Where
- 17 sites in Bulgaria, Estonia and 5 more
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
The purpose of this study evaluates the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who were heterozygous for F508del and a minimal function mutation (F/MF participants).
- Trial name
- NCT05033080
- Testing
- VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA
- Where
- 139 sites in United States, Australia and 10 more
- Volunteers
- 435 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF
This project is an attempt to understand how Orkambi treatment affects exercise capacity and the function of the arteries in CF patients who are homozygous F508del.
- Trial name
- NCT03338595
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Augusta University
Mucoviscidosis
Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)
Background The main risk factor for cervical cancer is the infection by human papillomavirus (HPV). Vaccination against HPV, offered to all girls aged 11 to 14 is an effective method of prevention against cervical pathology.
- Trial name
- NCT03653377
- Testing
- Self administrated questionnaire
- Where
- 7 sites in France
- Volunteers
- 81 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
- Conditions
- Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
- Trial name
- NCT06016088
- Testing
- RSP-1502, Tobramycin inhalation solution
- Where
- 22 sites in United States, Australia
- Volunteers
- 71 people
- Sponsor
- Respirion Pharmaceuticals Pty Ltd
Cystic Fibrosis in Children, Chronic Disease
Use of a Connected Companion in Children With Cystic Fibrosis
The study will be conducted over a 6 months period. For the first three months, the child will be accompagned with a connected companion.
- Trial name
- COMPANION-CF (NCT04705636)
- Testing
- Connected device named "Leo" from Ludocare society
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier de Saint-Brieuc
Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
This study investigated the efficacy of inhaled TOBI treatment for early infections of P. aeruginosa in paediatric patients with cystic fibrosis.
- Trial name
- EARLY (NCT01082367)
- Testing
- TOBI
- Where
- 19 sites in Canada, Egypt and 8 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals